Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CLDN6 CAR-NK cells

A preparation of autologous natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for the cell surface protein claudin 6 (CLDN6), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CLDN6 CAR-NK cells target and bind to CLDN6 expressed on the surface of tumor cells. This induces selective toxicity in tumor cells expressing CLDN6. CLDN6, a tight-junction protein and embryonic antigen, is expressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CLDN6-CAR-NKs
autologous Claudin6-targeted CAR-NK cells
autologous CLDN6-CAR-NK cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search